Liu C, Donahue J P, Heath L S, Turnbough C L
Department of Microbiology, University of Alabama, Birmingham 35294.
J Bacteriol. 1993 Apr;175(8):2363-9. doi: 10.1128/jb.175.8.2363-2369.1993.
The pyrBI operon of Escherichia coli K-12 encodes the two nonidentical subunits of the pyrimidine biosynthetic enzyme aspartate transcarbamylase (ATCase). Expression of this operon is negatively regulated by pyrimidine availability primarily through UTP-sensitive transcriptional attenuation and, to a lesser extent, at the level of transcriptional initiation. Previous studies indicated that the pyrBI operon was transcribed from tandem sigma 70 promoters designated P1 and P2, with the large majority of transcription initiated at the more downstream promoter P2. To more clearly define the roles of these promoters, mutations that severely impair or inactivate individual promoters were constructed in the chromosomal pyrBI operon, and their effects on ATCase synthesis were measured. In cells grown under conditions of either pyrimidine excess or pyrimidine limitation, more than 99% of all ATCase synthesis was directed by transcripts initiated at promoter P2, indicating that it is the only physiologically significant pyrBI promoter. However, mutations that effectively inactivate promoter P1 caused a 15% reduction in ATCase levels, apparently by inhibiting transcription from promoter P2 by an unknown mechanism. Support for this explanation was provided by the demonstration that little, if any, transcriptional initiation occurred at promoter P1 in a transcriptional fusion vector whereas a high level of transcription was initiated at promoter P2 in an equivalent construction. Our results also provide evidence for pyrimidine-mediated regulation of transcriptional initiation at promoter P2 over a severalfold range and show that cells can grow reasonably well with very low levels of ATCase, apparently because of changes in the concentration of allosteric effectors that increase the specific activity of the enzyme.
大肠杆菌K-12的pyrBI操纵子编码嘧啶生物合成酶天冬氨酸转氨甲酰酶(ATCase)的两个不同亚基。该操纵子的表达主要通过对UTP敏感的转录衰减受到嘧啶可用性的负调控,在较小程度上也受到转录起始水平的调控。先前的研究表明,pyrBI操纵子由串联的σ70启动子P1和P2转录,绝大多数转录起始于更下游的启动子P2。为了更清楚地确定这些启动子的作用,在染色体pyrBI操纵子中构建了严重损害或失活单个启动子的突变,并测量了它们对ATCase合成的影响。在嘧啶过量或嘧啶限制条件下生长的细胞中,所有ATCase合成的99%以上由起始于启动子P2的转录本指导,这表明它是唯一具有生理意义的pyrBI启动子。然而,有效失活启动子P1的突变导致ATCase水平降低15%,显然是通过一种未知机制抑制了启动子P2的转录。在转录融合载体中,启动子P1几乎没有转录起始(如果有的话),而在等效构建体中,启动子P2有高水平的转录起始,这一证明为这一解释提供了支持。我们的结果还提供了证据,表明嘧啶在几倍的范围内介导了对启动子P2转录起始的调控,并表明细胞在ATCase水平非常低的情况下仍能正常生长,显然是因为变构效应物浓度的变化增加了该酶的比活性。